News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome (PCOS) in Paediatric Populations



10/1/2013 10:50:19 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FREIENBACH, Switzerland--(BUSINESS WIRE)--EffRx Pharmaceuticals SA, the Swiss specialty pharmaceutical company, is pleased to announce that it has been awarded funding of EUR 5.9 million by the European Commission's 7th Framework Programme. The grant supports a consortium project for the development of EX404, effervescent metformin soluble, for PCOS (Grant no. 602243) in adolescent girls. The project, titled "Metfizz", is expected to run for 42 months. EffRx will co-ordinate the high-quality, pan-European consortium consisting of Klifo (DK), Sciprom (CH), Charles Campbell Associates (2000) Ltd. (UK), Sermes (ES), Randomized Clinical Trials (RCTs) (FR), and the University of Liverpool (UK).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
EffRx
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES